Metabolomic profiling and prognostication in CoVID-19 acute respiratory distress syndrome  

作　　者：David Furfaro Xiaoyu Che Wenhao Gou Matthew J.Cummings Nischay Mishra Daniel Brodie Thomas Briese Oliver Fiehn W.Ian Lipkin Max R.O'Donnell 

机构地区：[1]Division of Pulmonary,Critical Care,and Sleep Medicine at Beth Israel Deaconess Medical Center,MA,USA [2]Center for Infection and Immunity,Columbia University Irving Medical Center and the Mailman School of Public Health,NY,USA [3]Division of Pulmonary,Allergy,and Critical Care Medicine,Columbia University Irving Medical Center,NY,USA [4]Division of Pulmonary and Critical Care Medicine,The Johns Hopkins University School of Medicine,MD,USA [5]West Coast Metabolomics Center,University of California Davis,CA,USA

出　　处：《Journal of Intensive Medicine》2025年第1期108-110,共3页重症医学(英文)

基　　金：CHEST Foundation Grant in COVID-192020(DMF).

摘　　要：To the Editor,Coronavirus disease 2019(COVID-19)-related acute respiratory distress syndrome(ARDS)is biologically and clinically heterogeneous with a broad spectrum of organ dysfunction and illness severity.[1] In COVID-19-related ARDS(C-ARDS),two phenotypes have been identified with latent class analysis(LCA)that are associated with divergent clinical outcomes and response to corticosteroids,and correspond to previously identified hypoinflammatory and hyperinflammatory phenotypes,[2,3]Despite insights gained from this work,understanding the biological processes that determine mortality risk in C-ARDS remains imprecise.Here,we report that metabolomic profiling of plasma at the onset of C-ARDS provides insights into pathogenesis and may predict clinical outcomes.

关 键 词：DISTRESS ACUTE Metab 

分 类 号：R56[医药卫生—呼吸系统]